A new research has revealed that an injection of a new experimental drug might be able to reduce heart attacks risks by decreasing cholesterol levels up to 75 per cent when combined with statin.
The findings showed that the drug evolocumab played a crucial role in lowering "bad" cholesterol levels, which is the main cause of maximum heart risks when given with the usual dose of statin, the Daily Express reported.
When the injection of drug is given, every two weeks or monthly, it blocks the substance which obstructs the liver's ability to eliminate cholesterol from the blood.
Julie Ward of the British Heart Foundation said that although the treatment is proving its worth, other factors like quite smoking, eating healthy and moderate exercising also play a vital role in curbing the health risks.
However, the report notified that further comprehensive research on the drug is still required for security and to determine the long term results.
The study results were published in Jama, the Journal of the American Medical Association.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.